TOMI Environmental Solutions, Inc. (TOMZ) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Q2 2026 revenue reached $2.25 million, a 118% increase year-over-year and a 36% sequential increase from Q1 2026.

Product Revenue: $1.86 million, up 185% year-over-year and 42% sequentially.

Service Revenue: $389,000, a 3% increase year-over-year and 13% sequentially.

Gross Margin: Improved to 61.7%, up from 50.3% in Q1 2026 and 65.7% in Q2 2025.

Operating Expenses: Reduced by 10% year-over-year to $1.63 million.

Net Loss: Decreased by 69% to approximately $382,000 ($0.05 per share), compared to a net loss of $1.24 million in Q2 2025.

Cash and Cash Equivalents: Increased to $322,000 from $88,000 at year-end 2025.

Backlog: Grew to $2.6 million post-quarter from $2.2 million at quarter-end.

2Strategic Updates and Business Highlights

Integration with Carbonium Core: Progressing as planned, with a focus on merging complementary technologies.

SteraMist Growth: Continued growth in BIT Solution sales, mobile equipment, and single applicators.

New Partnerships: Established collaborations with a Fortune 500 medical device manufacturer and expanded distribution networks domestically and internationally.

Regulatory Approvals: Achieved significant milestones in obtaining international approvals and advancing the 510(k) submission process for medical device applications.

Product Development: Launched a new hybrid system and continued development of next-generation iHP chambers for various applications.

3Forward Guidance and Outlook

Revenue Guidance: Reaffirmed full-year 2026 revenue guidance of at least $12 million, supported by a robust sales pipeline of approximately $35 million.

Operational Goals: Targeting breakeven by Q4 2026, with ongoing cost management and revenue growth strategies.

Merger with Carbonium Core: Anticipated to enhance the combined company’s balance sheet and growth trajectory, pending $10 million financing condition.

4Bad News, Challenges, or Points of Concern

Operating Loss: Despite improvements, the company still reported an operating loss of $244,000.

Transaction Costs: Elevated advisory and legal fees related to the Carbonium merger, approximately $300,000 in Q2 2026, which may impact profitability.

Regulatory Risks: Ongoing efforts to secure FDA and other regulatory approvals, which are critical for expanding market opportunities.

Market Competition: The company faces competition in the biodefense and medical device sectors, necessitating continuous innovation and adaptation.

5Notable Q&A Insights

AgriMist Product: Expected to add to the sales pipeline once commercialized.

Medical Device Clearance: Next milestones involve conducting and reporting studies to the FDA, with timelines still uncertain.

Carbonium Core Diligence: The merger is contingent on NASDAQ compliance and raising necessary financing.

FEMA Engagement: TOMI has existing relationships with FEMA, though specific uses of equipment in disaster response are not publicly disclosed.

Tariff Impact: No current tariffs affecting operations were reported, but this remains an area for monitoring.

Path to Profitability: Management is optimistic about reaching breakeven by Q4 2026 based on revenue growth and cost management. Overall, TOMI Environmental Solutions reported strong financial growth in Q2 2026, driven by strategic initiatives and partnerships, while also navigating challenges related to operating losses and regulatory approvals. The outlook remains positive with reaffirmed revenue guidance and a solid sales pipeline.